Hengrui Pharma(SH:600276) Xin Lang Cai Jing·2025-12-28 23:24Core Viewpoint - Hansoh Pharmaceutical has entered into a licensing agreement with Jiangsu Hengrui Medicine Co., Ltd. to develop, produce, and commercialize SHR6508 in mainland China, excluding Hong Kong, Macau, and Taiwan [1] Group 1: Licensing Agreement Details - The agreement grants Hansoh Pharmaceutical exclusive rights to SHR6508, which is currently in Phase III clinical trials for treating secondary hyperparathyroidism in adult patients undergoing hemodialysis due to chronic kidney disease [1] - Hansoh Pharmaceutical will pay an upfront fee of 30 million RMB, with potential milestone payments of up to 190 million RMB based on regulatory and commercial achievements [1] - The company will also pay tiered royalties based on future net sales of the product [1]